MicuRx raises $55M in series C

Antibiotics company MicuRx Pharmaceuticals Inc. (Hayward, Calif.) raised $55 million in a series C round led by GP Healthcare Capital. New investors GP TMT Capital, 3E Bioventures Capital and Delian Capital also participated.

MicuRx said it will use the funds to complete a Phase III trial in China of MRX-I to treat complicated skin and skin structure infections (cSSSIs), and to complete one pivotal, U.S. Phase III study to treat acute bacterial skin and skin structure infections (ABSSSIs). ...